Skip to the lineages
Regenerative Medicine

PRP vs. Hyaluronic Acid for Knee Osteoarthritis: How Do Functional Outcomes Compare?

Published November 16, 2026

Protocol: 7 steps in this guide
  1. PRP and viscosupplementation
  2. Function and pain are different outcomes
  3. How WOMAC is scored
  4. The two 2026 syntheses
  5. Certainty, heterogeneity and follow-up
  6. Severity and number of injections
  7. The guideline view and conservative care

On average, platelet-rich plasma (PRP) produced somewhat better WOMAC scores, a measure that includes function, than hyaluronic acid (HA) in two 2026 meta-analyses of randomized trials. One, pooling 28 trials, rated its WOMAC total-score benefit, which combines pain, stiffness and function, as moderate-certainty evidence; the other, pooling 21 trials, called the advantage “small.” Both found large differences between trials, and they disagreed on other measures and on which PRP preparations did best. A group average does not predict how much any one person’s knee function will change, and the 2026 VA/DoD guideline finds the evidence insufficient to recommend for or against either injection for knee osteoarthritis.

PRP and viscosupplementation

PRP is made from the patient’s own blood, concentrating platelets in plasma. HA injections, also called viscosupplementation, inject hyaluronic acid into the knee. Both are injected into the joint and both are used for knee osteoarthritis pain. How PRP is made is covered in how platelet-rich plasma is made from a blood sample.

Function and pain are different outcomes

Function means what you can do: walk, climb stairs, get up from a chair. Pain is how much it hurts. Trials measure them separately, and an injection can change one more than the other. This article focuses on function; how long pain relief lasts compared with a steroid injection is covered in PRP vs. corticosteroid injections for knee osteoarthritis.

How WOMAC is scored

WOMAC, the Western Ontario and McMaster Universities Osteoarthritis Index, is a questionnaire about knee pain, stiffness and physical function. In the Journal of ISAKOS review below, a negative mean difference in WOMAC indicated greater improvement with PRP. Other function measures used in these trials include KOOS, the Knee Injury and Osteoarthritis Outcome Score, and the IKDC score.

The two 2026 syntheses

Feature Abduljabbar and colleagues, Journal of ISAKOS (2026) Zhong and colleagues, Arthroscopy (2026)
Trials and participants 28 RCTs, 2,685 participants 21 RCTs, 1,790 patients
Search through April 14, 2026 August 2025
WOMAC (total score in the ISAKOS review) Better with PRP: mean difference -8.14 (95% CI -10.79 to -5.48); moderate certainty Favored PRP at all time points
Pain (VAS) Better with PRP: mean difference -7.89; low certainty No significant advantage at 3 and 6 months; better with PRP at 12 months
KOOS and IKDC Not reported in the abstract No significant differences
Heterogeneity Very high (I² 96% for WOMAC) Substantial heterogeneity and risk of bias reported
Which PRP did best Leukocyte-poor PRP, multiple injections, Kellgren-Lawrence grade I to II High-concentration, leukocyte-rich and activated PRP at 12 months

The Journal of ISAKOS review is published as Platelet-rich plasma provides greater pain relief and functional improvement than hyaluronic acid for knee osteoarthritis. The two reviews agree that PRP improved WOMAC scores more than HA. They differ on whether pain improved at every time point, on the other function scales, and on which type of PRP worked best: one favored leukocyte-poor preparations and the other leukocyte-rich ones. Those differences can come from which trials each included, when each searched, and which outcomes each pooled. The leukocyte question is covered in how leukocyte-rich and leukocyte-poor PRP differ.

Certainty, heterogeneity and follow-up

Very high heterogeneity means the individual trials disagreed a lot with one another, so the pooled average hides a wide spread. The Journal of ISAKOS review found that disease severity and injection number explained “approximately 24% of the between-study variance,” and that restricting to low-risk trials “attenuated but did not nullify the advantage of PRP.” The Arthroscopy review said its findings “should be interpreted cautiously and reflect short-term to 12-month outcomes only.” What counts as a change large enough to matter is covered in what clinically meaningful improvement means in a joint pain study.

Severity and number of injections

The Journal of ISAKOS review concluded: “The largest benefit is to be expected in mild-to-moderate disease treated with leukocyte-poor PRP in a multiple-injection protocol.” It also stated: “HA remains a reasonable alternative.” The Arthroscopy review, by contrast, found that injection frequency “showed no consistent effect.” Injection schedules are covered in how many PRP injections are typically given in a treatment series.

The guideline view and conservative care

The VA/DoD Clinical Practice Guideline for the Non-Surgical Management of Hip & Knee Osteoarthritis (May 2026), based on evidence through July 31, 2025, finds insufficient evidence to recommend for or against either PRP or a viscosupplementation injection for persistent knee osteoarthritis pain. In its PRP discussion it cites a review of 42 trials comparing PRP with HA in which PRP “did not consistently outperform HA by a statistically significant margin.” The same guideline suggests “a structured physical therapy program” for hip and knee osteoarthritis. An injection can be discussed alongside exercise and other conservative care, not instead of it; the broader PRP evidence is in what the evidence says about PRP for knee osteoarthritis.

Two 2026 meta-analyses found that PRP improved WOMAC scores, which include function, somewhat more than hyaluronic acid on average, but the trials varied widely, the reviews disagreed on pain and on the best PRP type, and the VA/DoD guideline remains neutral, so PRP may offer a modest functional edge without any guarantee for an individual knee.

Cells linked to this one

This guide leads on to

Lineage H: Head-to-Head Treatment Comparisons

What readers added

Add a remark

Your email address will not be published. Required fields are marked *